Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

BACKGROUND: Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may provide a more attractive option for the treatmen...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer
Egile Nagusiak: Xu, Ke, Park, Dongkyoo, Magis, Andrew T., Zhang, Jun, Zhou, Wei, Sica, Gabriel L., Ramalingam, Suresh S., Curran, Walter J., Deng, Xingming
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6456974/
https://ncbi.nlm.nih.gov/pubmed/30971271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-019-1012-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak